Tuesday, 20 September 2011

Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial

Source PR Newswire:
 Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta™ (oral estriol) drug candidate for relapsing-remitting multiple sclerosis (MS) in women, per the original protocol.  Read more here.